Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis exec joins Genmab

Dr Judith Klimovsky becomes chief development officer

Copenhagen, Denmark-based Genmab has appointed Dr Judith Klimovsky as executive vice president and chief development officer.

Based out of the biotech's Princeton, US office, Dr Klimovsky will be responsible for the company's global product development strategy.

She joins Genmab from Novartis, where she most recently served as senior vice president and global head of oncology clinical development, having previously served as head of the global programme for cancer drug Afinitor.

Prior to this, Dr Klimovsky held director-level positions at Merck & Co in the US, and Bristol-Myers Squibb in South America.

Jan van de Winkel, Genmab's chief executive, said: “We are very pleased to welcome Judith to Genmab.

“She has a strong track record and skills in cancer drug development which will further strengthen the company as we build a winning team to continue our success in the future on the road to becoming a sustainably profitable biotech company.

“With Judith heading our product development efforts we will be able to bring forward truly differentiated products that have the potential to transform the treatment of cancer and provide great benefits to patients and their families in the future.”

10th February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics